Core Laboratories (NYSE:CLB) Raised to Hold at Wall Street Zen

by · The Cerbat Gem

Core Laboratories (NYSE:CLB – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings downgraded shares of Core Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce”.

Read Our Latest Stock Analysis on Core Laboratories

Core Laboratories Price Performance

Shares of CLB stock opened at $10.65 on Friday. Core Laboratories has a twelve month low of $9.72 and a twelve month high of $20.36. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 0.41. The stock has a fifty day simple moving average of $12.01 and a two-hundred day simple moving average of $15.20. The stock has a market capitalization of $488.53 million, a price-to-earnings ratio of 19.01, a P/E/G ratio of 2.57 and a beta of 1.03.

Core Laboratories (NYSE:CLB – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The firm had revenue of $124.61 million for the quarter, compared to analyst estimates of $126.26 million. Core Laboratories had a return on equity of 10.03% and a net margin of 5.10%.The business’s revenue for the quarter was down 4.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.19 earnings per share. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. On average, analysts predict that Core Laboratories will post 0.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CLB. Heartland Advisors Inc. bought a new stake in Core Laboratories during the first quarter valued at about $2,518,000. UBS Group AG raised its holdings in Core Laboratories by 32.9% in the fourth quarter. UBS Group AG now owns 412,515 shares of the oil and gas company’s stock worth $6,613,000 after purchasing an additional 102,151 shares in the last quarter. Terril Brothers Inc. purchased a new stake in shares of Core Laboratories during the fourth quarter valued at about $304,000. Swiss Life Asset Management Ltd purchased a new stake in shares of Core Laboratories during the fourth quarter valued at about $192,000. Finally, Abacus Wealth Partners LLC bought a new position in shares of Core Laboratories during the 4th quarter worth approximately $233,000. 97.81% of the stock is owned by institutional investors.

Core Laboratories News Roundup

Here are the key news stories impacting Core Laboratories this week:

  • Positive Sentiment: Core Laboratories reported second-quarter adjusted EPS of $0.11, above the $0.08 analyst consensus. Production Enhancement performance helped offset weakness in the Reservoir Description business. Core Laboratories Q2 Earnings Beat Estimates, Decline Y/Y
  • Positive Sentiment: Operating income excluding special items increased 42% sequentially, while adjusted EPS rose 85% from the prior quarter. The company also repurchased 214,712 shares for $2.7 million, supporting per-share value. Core Lab Reports Second Quarter 2026 Results
  • Positive Sentiment: Management and analysts described the earnings call as indicating a gradual recovery, with sequential revenue and profitability improvement providing a potential foundation for a broader turnaround. Core Laboratories Earnings Call Signals Gradual Recovery
  • Neutral Sentiment: Core Laboratories declared a $0.01 quarterly dividend, payable August 31 to shareholders of record August 10. The dividend provides income support, but its annualized yield is only about 0.4%.
  • Negative Sentiment: Second-quarter revenue fell 4.3% year over year to $124.6 million, below the roughly $126.3 million consensus, while adjusted EPS declined from $0.19 a year earlier. Free cash flow was modest at $3.1 million. Is CLB Stock Attractive After Its Sharp Selloff and Mixed Q2 Results?
  • Negative Sentiment: Third-quarter EPS guidance of $0.12–$0.20 is broad and includes a level below the $0.17 consensus estimate. The company expects revenue of $128.5–$135.5 million, signaling only a gradual recovery. Analysts also remain cautious after a sharp six-month selloff and ongoing geopolitical pressure.

About Core Laboratories

(Get Free Report)

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.

Further Reading